Development of a penem antibiotic against Mycobacteroides abscessus

Batchelder et al. report a new penem class antibiotic, T405, which exhibits potent activity against M. abscessus and clinical isolates from cystic fibrosis patients. The development of resistance to T405 is inhibited with the addition of a β-lactamase inhibitor, avibactam. Its clinical potential is...

Full description

Bibliographic Details
Main Authors:	Hunter R. Batchelder, Elizabeth Story-Roller, Evan P. Lloyd, Amit Kaushik, Kristina M. Bigelow, Emily C. Maggioncalda, Eric L. Nuermberger, Gyanu Lamichhane, Craig A. Townsend
Format:	Article
Language:	English
Published:	Nature Publishing Group 2020-12-01
Series:	Communications Biology
Online Access:	https://doi.org/10.1038/s42003-020-01475-2

id	doaj-5e507dd0a49447c7b96b6dc7becd6906
record_format	Article
spelling	doaj-5e507dd0a49447c7b96b6dc7becd69062020-12-07T23:45:27ZengNature Publishing GroupCommunications Biology2399-36422020-12-01311510.1038/s42003-020-01475-2Development of a penem antibiotic against Mycobacteroides abscessusHunter R. Batchelder0Elizabeth Story-Roller1Evan P. Lloyd2Amit Kaushik3Kristina M. Bigelow4Emily C. Maggioncalda5Eric L. Nuermberger6Gyanu Lamichhane7Craig A. Townsend8Department of Chemistry, Johns Hopkins UniversityCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineDepartment of Chemistry, Johns Hopkins UniversityCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of MedicineDepartment of Chemistry, Johns Hopkins UniversityBatchelder et al. report a new penem class antibiotic, T405, which exhibits potent activity against M. abscessus and clinical isolates from cystic fibrosis patients. The development of resistance to T405 is inhibited with the addition of a β-lactamase inhibitor, avibactam. Its clinical potential is further demonstrated by T405 displaying a favourable pharmacokinetic profile in mice with an absence of toxicity.https://doi.org/10.1038/s42003-020-01475-2
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hunter R. Batchelder Elizabeth Story-Roller Evan P. Lloyd Amit Kaushik Kristina M. Bigelow Emily C. Maggioncalda Eric L. Nuermberger Gyanu Lamichhane Craig A. Townsend
spellingShingle	Hunter R. Batchelder Elizabeth Story-Roller Evan P. Lloyd Amit Kaushik Kristina M. Bigelow Emily C. Maggioncalda Eric L. Nuermberger Gyanu Lamichhane Craig A. Townsend Development of a penem antibiotic against Mycobacteroides abscessus Communications Biology
author_facet	Hunter R. Batchelder Elizabeth Story-Roller Evan P. Lloyd Amit Kaushik Kristina M. Bigelow Emily C. Maggioncalda Eric L. Nuermberger Gyanu Lamichhane Craig A. Townsend
author_sort	Hunter R. Batchelder
title	Development of a penem antibiotic against Mycobacteroides abscessus
title_short	Development of a penem antibiotic against Mycobacteroides abscessus
title_full	Development of a penem antibiotic against Mycobacteroides abscessus
title_fullStr	Development of a penem antibiotic against Mycobacteroides abscessus
title_full_unstemmed	Development of a penem antibiotic against Mycobacteroides abscessus
title_sort	development of a penem antibiotic against mycobacteroides abscessus
publisher	Nature Publishing Group
series	Communications Biology
issn	2399-3642
publishDate	2020-12-01
description	Batchelder et al. report a new penem class antibiotic, T405, which exhibits potent activity against M. abscessus and clinical isolates from cystic fibrosis patients. The development of resistance to T405 is inhibited with the addition of a β-lactamase inhibitor, avibactam. Its clinical potential is further demonstrated by T405 displaying a favourable pharmacokinetic profile in mice with an absence of toxicity.
url	https://doi.org/10.1038/s42003-020-01475-2
work_keys_str_mv	AT hunterrbatchelder developmentofapenemantibioticagainstmycobacteroidesabscessus AT elizabethstoryroller developmentofapenemantibioticagainstmycobacteroidesabscessus AT evanplloyd developmentofapenemantibioticagainstmycobacteroidesabscessus AT amitkaushik developmentofapenemantibioticagainstmycobacteroidesabscessus AT kristinambigelow developmentofapenemantibioticagainstmycobacteroidesabscessus AT emilycmaggioncalda developmentofapenemantibioticagainstmycobacteroidesabscessus AT ericlnuermberger developmentofapenemantibioticagainstmycobacteroidesabscessus AT gyanulamichhane developmentofapenemantibioticagainstmycobacteroidesabscessus AT craigatownsend developmentofapenemantibioticagainstmycobacteroidesabscessus
_version_	1724397031951171584

Development of a penem antibiotic against Mycobacteroides abscessus

Similar Items